{"id":63660,"date":"2026-04-21T23:17:30","date_gmt":"2026-04-21T15:17:30","guid":{"rendered":"https:\/\/flcube.com\/?p=63660"},"modified":"2026-04-21T23:17:30","modified_gmt":"2026-04-21T15:17:30","slug":"cspcs-albumin-bound-sirolimus-hb1901-meets-primary-endpoint-in-phase-ib-iii-trial-for-rare-pecoma-reinforcing-breakthrough-therapy-status","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63660","title":{"rendered":"CSPC\u2019s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib\/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status"},"content":{"rendered":"\n

CSPC Pharmaceutical Group Ltd.<\/strong> (HKG: 1093<\/a>) announced that its pivotal Phase Ib\/III clinical trial<\/strong> of HB1901<\/strong>, an albumin-bound nanoparticle formulation of sirolimus<\/strong>, has met its primary endpoint<\/strong> in patients with advanced malignant perivascular epithelioid cell tumor (PEComa)<\/strong>\u2014a rare and aggressive mesenchymal malignancy. The study demonstrated superior anti-tumor efficacy, clinical benefit, and safety\/tolerability<\/strong> compared to investigator\u2019s choice of standard regimens<\/strong>, positioning HB1901 as a potential new standard of care for this orphan indication.<\/p>\n\n\n\n

Disease & Drug Profile<\/h2>\n\n\n\n
Attribute<\/th>Detail<\/th><\/tr><\/thead>
Indication<\/strong><\/td>Advanced malignant PEComa<\/strong>\u2014a rare tumor of perivascular epithelioid cells with limited treatment options<\/td><\/tr>
Molecule<\/strong><\/td>HB1901<\/strong>: Albumin-bound nanoparticle suspension of sirolimus<\/strong> (rapamycin)<\/td><\/tr>
Drug Class<\/strong><\/td>Category 2.2<\/strong> (new formulation of known active ingredient)<\/td><\/tr>
Mechanism<\/strong><\/td>Inhibits mTOR pathway<\/strong>, a key driver of PEComa growth; albumin binding enhances tumor delivery and reduces systemic toxicity<\/td><\/tr>
Regulatory Status<\/strong><\/td>Granted Breakthrough Therapy Designation (BTD)<\/strong> by China\u2019s NMPA<\/strong> in February 2025<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

PEComa affects fewer than 1 in 1 million people annually<\/strong>, often presenting with metastatic disease and poor response to conventional chemotherapy. Prior to HB1901, no therapy had demonstrated robust, reproducible efficacy in controlled trials.<\/p>\n\n\n\n

Trial Design & Outcomes<\/h2>\n\n\n\n